Monograph Wealth Advisors, LLC Alnylam Pharmaceuticals, Inc. Transaction History
Monograph Wealth Advisors, LLC
- $690 Million
- Q1 2025
A detailed history of Monograph Wealth Advisors, LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Monograph Wealth Advisors, LLC holds 2,126 shares of ALNY stock, worth $722,414. This represents 0.08% of its overall portfolio holdings.
Number of Shares
2,126
Previous 2,138
0.56%
Holding current value
$722,414
Previous $503,000
14.12%
% of portfolio
0.08%
Previous 0.07%
Shares
8 transactions
Others Institutions Holding ALNY
# of Institutions
724Shares Held
111MCall Options Held
966KPut Options Held
853K-
Capital World Investors Los Angeles, CA16.7MShares$5.69 Billion0.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$4.44 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$3.24 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.15MShares$2.43 Billion0.44% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.42MShares$1.5 Billion0.79% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $41.8B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...